Evidence Level
Bone Marrow supplementation is supported by ancestral nutrition principles and preclinical research on its bioactive compounds. Alkylglycerols, initially studied by Brohult et al. (1986) for their immune-modulating effects, have demonstrated immunostimulatory properties across multiple preclinical models. A comprehensive review by Denisenko et al. (2019) in Marine Drugs further confirmed their role in immune cell membrane function and signaling. Additionally, bone marrow's fat-soluble vitamin profile, particularly vitamin K2 (MK-4), has been linked to bone and cardiovascular health, supported by findings from the Rotterdam Study (Geleijnse et al., 2004) and subsequent trials.
Recent clinical studies highlight bone marrow's therapeutic potential in various conditions. Jawanda et al. (2024) conducted a systematic review and network meta-analysis involving 48 studies (9,338 knees), concluding that platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and hyaluronic acid (HA) injections outperformed corticosteroids in pain relief and functional improvement for knee osteoarthritis at ≥6 months. Similarly, Zhu et al. (2024) found that core decompression combined with bone marrow mononuclear cells improved visual analog scale scores more effectively than core decompression alone in treating femoral head necrosis, based on a meta-analysis of eight studies (n=370 participants).
In cardiovascular applications, Kalou et al. (2023) reviewed 10 RCTs (n=725) and found that bone marrow-derived mesenchymal stem cells (BM-MSCs) improved left ventricular ejection fraction (LVEF) by 6.37% and six-minute walk distance (6MWD) by 27.86 meters in heart failure patients. Despite these promising findings, large-scale randomized controlled trials (RCTs) specifically evaluating whole bone marrow supplements remain limited. Nonetheless, the nutrient density of bone marrow and its traditional use provide a rationale for supplementation.